Benefits
Methemoglobinemia Treatment (Established Pharmaceutical Use)
FDA-approved emergency treatment for acquired methemoglobinemia (oxidized hemoglobin can't carry oxygen). 1-2 mg/kg IV reduces methemoglobin to functional hemoglobin. Foundational legitimate medical use.
Ifosfamide-Induced Encephalopathy
Used to reverse encephalopathy caused by chemotherapy ifosfamide. Specific oncology indication.
Mitochondrial Function Support (Theoretical / Animal Models)
Animal studies show methylene blue supports mitochondrial electron transport chain — donates electrons to complex IV (cytochrome c oxidase). Theoretical 'mitochondrial nootropic' mechanism. Human clinical translation incomplete.
Cognitive Function (Limited Human Evidence)
Rodriguez 2016 trial of low-dose methylene blue (280 mg/kg) showed enhanced memory consolidation in healthy adults via fMRI. Limited rigorous trials. Most claims based on animal studies and theoretical mechanism.
Alzheimer's Research (Failed Trials)
TauRx Therapeutics tested methylene blue derivative LMTM (LMTX®) in Phase 3 Alzheimer's trials — FAILED to show benefit. Continues research interest. Original methylene blue not specifically approved for AD.
Antimalarial / Antimicrobial (Historical and Limited Modern)
Used historically for malaria; antimicrobial activity. Modern use limited to specific contexts.
Mechanism of action
Methemoglobin Reduction
Methylene blue is reduced to leukomethylene blue by NADPH-methemoglobin reductase; leukomethylene blue then reduces methemoglobin (Fe3+) back to hemoglobin (Fe2+). Foundational pharmaceutical mechanism.
Mitochondrial Electron Transport Chain Donation
At low doses, methylene blue can act as ELECTRON CARRIER between NADH and cytochrome c oxidase (complex IV) in mitochondrial ETC. Theoretical bypass of electron transport bottlenecks in stressed mitochondria. Basis for nootropic claims.
MAO Inhibition
Methylene blue is a POTENT MAO-A INHIBITOR — significant clinical implication for serotonin syndrome risk with serotonergic medications. Not a typical 'side effect' but core pharmacology.
Nitric Oxide Synthase Inhibition
Inhibits NO synthase — modulates NO/cGMP signaling. Multiple downstream effects.
Tau Aggregation Inhibition (Alzheimer's Mechanism)
Inhibits tau protein aggregation — basis for Alzheimer's research direction (LMTX® failed in clinical trials).
Clinical trials
RCT of single dose methylene blue (280 mg/kg) vs placebo on memory tasks with fMRI in 26 healthy adults.
26 healthy adults.
Improved memory retrieval and increased fMRI activity in memory-related brain areas. Single dose; small sample; generated continued research interest.
Phase 3 RCT of LMTM (200 mg/day) vs placebo monotherapy or as add-on in Alzheimer's patients.
Alzheimer's patients.
FAILED to show benefit on primary outcomes. Significant disappointment for tau-targeting Alzheimer's strategy. Generated questions about methylene blue derivatives' clinical utility.
About this ingredient
METHYLENE BLUE (METHYLTHIONINIUM CHLORIDE) is a SYNTHETIC PHENOTHIAZINE DYE first synthesized by Heinrich Caro in 1876. Multiple historical uses: textile dye, histological stain (showing nerve cells in tissue sections — basis for Nobel-winning Cajal/Golgi work), antimalarial drug (early use), antiseptic. FDA-APPROVED PRESCRIPTION USES: (1) ACQUIRED METHEMOGLOBINEMIA — emergency treatment; (2) Ifosfamide-induced encephalopathy. RECENT 'BIOHACKING' POPULARITY: low-dose methylene blue for cognition, mitochondrial function, longevity — limited rigorous evidence supporting this; theoretical mechanism based on mitochondrial ETC modulation.
CRITICAL POSITIONING: METHYLENE BLUE IS A DRUG, NOT A 'NATURAL SUPPLEMENT' — has potent pharmacologic effects, significant drug interactions (especially serotonergic medications), and contraindications.
CRITICAL SAFETY CAUTIONS: (1) PHARMACEUTICAL-GRADE VS NON-PHARMACEUTICAL — AQUARIUM/INDUSTRIAL methylene blue contains TOXIC IMPURITIES (heavy metals, contaminants) — NEVER consume non-pharmaceutical-grade methylene blue; ONLY USP-GRADE / pharmaceutical methylene blue is appropriate; this is LIFE-THREATENING distinction; reputable suppliers provide certificates of analysis; (2) SEROTONIN SYNDROME — methylene blue is potent MAO-A inhibitor; combination with serotonergic medications (SSRIs, SNRIs, MAOIs, TCAs, triptans, tramadol, St. John's wort, MDMA) can cause SEVERE/FATAL serotonin syndrome; many people are on these medications without realizing the interaction; FDA black box warning; WASHOUT PERIODS needed: 5-6 weeks for fluoxetine, 2 weeks for most other SSRIs, 4 weeks for paroxetine, etc.; (3) G6PD DEFICIENCY — CONTRAINDICATED; methylene blue causes hemolysis in G6PD-deficient individuals (paradoxical, since it's used to treat methemoglobinemia in normal individuals); G6PD deficiency is common in some populations (Mediterranean, African, Asian descent); test before use if uncertain; (4) PREGNANCY/LACTATION — AVOID; potential fetal harm and milk excretion; (5) BLUE URINE / TISSUE STAINING — universal effect; harmless but startling; can persist for hours/days; surgical patients on methylene blue may have permanent or prolonged tissue staining at surgical sites; (6) DOSE — pharmaceutical methemoglobinemia: 1-2 mg/kg IV; biohacking oral: variable claims of 0.5-4 mg/day; HIGHER doses (>10 mg) have more drug-like effects and risks; (7) PARADOXICAL METHEMOGLOBINEMIA — at HIGH doses, methylene blue itself can CAUSE methemoglobinemia; biphasic dose-response; relevant for those self-administering high doses; (8) ANESTHESIA INTERACTIONS — disclose methylene blue use to anesthesiologist; multiple interactions; (9) PEDIATRIC USE — emergency methemoglobinemia treatment in children appropriate; non-emergency use in children NOT appropriate; (10) BIOHACKING CLAIMS — methylene blue has accumulated extensive 'biohacking' claims (nootropic, anti-aging, mitochondrial enhancement, depression, COVID treatment, etc.); rigorous human evidence is LIMITED; some animal studies and small human trials suggestive; NOT EQUIVALENT to evidence base for established pharmaceuticals; (11) RECENT FAILURES — LMTM (methylene blue derivative for Alzheimer's) FAILED Phase 3; methylene blue for COVID had minimal evidence; many 'biohacking' claims have not been rigorously confirmed; (12) FOR PHARMACEUTICAL USE — methemoglobinemia, ifosfamide encephalopathy: legitimate medical applications; (13) FOR EXPERIMENTAL/BIOHACKING USE — at minimum: pharmaceutical-grade product, awareness of all medications and conditions for interactions, low starting dose, ideally medical supervision; the combination of drug-like effects + lay self-administration + serotonergic interaction risks make this concerning territory; (14) The rapid popularity of methylene blue in biohacking communities does not match its evidence base or safety profile for casual use.